KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Finished Goods (2016 - 2020)

Historic Finished Goods for Emergent BioSolutions (EBS) over the last 11 years, with Q1 2020 value amounting to $56.2 million.

  • Emergent BioSolutions' Finished Goods changed N/A to $56.2 million in Q1 2020 from the same period last year, while for Mar 2020 it was $56.2 million, marking a year-over-year change of. This contributed to the annual value of $62.3 million for FY2019, which is 2263.78% up from last year.
  • According to the latest figures from Q1 2020, Emergent BioSolutions' Finished Goods is $56.2 million.
  • In the past 5 years, Emergent BioSolutions' Finished Goods registered a high of $62.3 million during Q4 2019, and its lowest value of $10.1 million during Q1 2017.
  • In the last 5 years, Emergent BioSolutions' Finished Goods had a median value of $27.3 million in 2016 and averaged $33.0 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Finished Goods tumbled by 5887.78% in 2017, and later skyrocketed by 26508.58% in 2018.
  • Over the past 5 years, Emergent BioSolutions' Finished Goods (Quarter) stood at $23.5 million in 2016, then grew by 28.12% to $30.1 million in 2017, then soared by 68.77% to $50.8 million in 2018, then grew by 22.64% to $62.3 million in 2019, then decreased by 9.79% to $56.2 million in 2020.
  • Its last three reported values are $56.2 million in Q1 2020, $62.3 million for Q4 2019, and $54.6 million during Q3 2019.